Galanthamine from Smart BioProcessing of Daffodils
Lead Participant:
FARMACEUTICAL INNOVATIONS LIMITED
Abstract
This short feasibility project aim at improving the industrial process of extraction of Galanthamine, a Daffodil derived alkaloid, presently used for the treatment of moderate Alzheimer’s,
the production of anti-nicotine patches, and hair growth stimulants for the cosmetic industry.
Galanthamine is one of the few medical drugs that is approved by NICE to treat Alzheimer's, a disease that affects 35 millions of people worldwide.
This will support broader activities aimed at developing an UK-based supply chain aimed at producing and selling the pharmaceutical.
the production of anti-nicotine patches, and hair growth stimulants for the cosmetic industry.
Galanthamine is one of the few medical drugs that is approved by NICE to treat Alzheimer's, a disease that affects 35 millions of people worldwide.
This will support broader activities aimed at developing an UK-based supply chain aimed at producing and selling the pharmaceutical.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| FARMACEUTICAL INNOVATIONS LIMITED | £49,035 | £ 33,079 |
Participant |
||
| BANGOR UNIVERSITY N WALES | £71,035 | £ 71,035 |
| AGROCEUTICAL PRODUCTS LTD | £31,352 | £ 12,002 |
People |
ORCID iD |